NasdaqCM:PLSE

Stock Analysis Report

Executive Summary

Pulse Biosciences, Inc. operates as a clinical stage medical therapy company.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Risks

  • Pulse Biosciences has significant price volatility in the past 3 months.
  • Pulse Biosciences is covered by less than 3 analysts.

Share Price & News

How has Pulse Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

14.1%

PLSE

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

19.4%

PLSE

9.9%

US Medical Equipment

0.6%

US Market

PLSE outperformed the Medical Equipment industry which returned 9.5% over the past year.

PLSE outperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

PLSEIndustryMarket
7 Day14.1%1.1%-0.6%
30 Day37.8%0.6%2.2%
90 Day39.4%2.9%1.1%
1 Year19.4%19.4%10.8%9.9%2.9%0.6%
3 Year162.4%162.4%70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Pulse Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pulse Biosciences undervalued based on future cash flows and its price relative to the stock market?

6.89x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Pulse Biosciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Pulse Biosciences to establish if it is available at substantial discount.


Price Based on Earnings

Pulse Biosciences is loss making, we can't compare its value to the US Medical Equipment industry average.

Pulse Biosciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Pulse Biosciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Pulse Biosciences is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Pulse Biosciences expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pulse Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Pulse Biosciences performed over the past 5 years?

-57.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Pulse Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Pulse Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Pulse Biosciences's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Pulse Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Pulse Biosciences has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Pulse Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Pulse Biosciences's financial position?


Financial Position Analysis

Pulse Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Pulse Biosciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Pulse Biosciences's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Pulse Biosciences's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are -1.0031768169968E+17x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Pulse Biosciences has sufficient cash runway for 1.4 years based on current free cash flow.

Pulse Biosciences has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 51.2% each year.


Next Steps

Dividend

What is Pulse Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Pulse Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Pulse Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Pulse Biosciences has not reported any payouts.

Unable to verify if Pulse Biosciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Pulse Biosciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Pulse Biosciences's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Darrin Uecker (53yo)

4yrs

Tenure

US$569,437

Compensation

Mr. Darrin R. Uecker has been the Chief Executive Officer and President at Pulse Biosciences, Inc. since September 2015. Mr. Uecker served as the Chief of Operating Officer of Progyny, Inc. since 2014 and  ...


CEO Compensation Analysis

Darrin's remuneration is lower than average for companies of similar size in United States of America.

Darrin's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.8yrs

Average Tenure

53yo

Average Age

The tenure for the Pulse Biosciences management team is about average.


Board Age and Tenure

1.8yrs

Average Tenure

59yo

Average Age

The average tenure for the Pulse Biosciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Darrin Uecker (53yo)

    President

    • Tenure: 4yrs
    • Compensation: US$569.44k
  • Ed Ebbers (59yo)

    Executive VP & GM of Dermatology

    • Tenure: 0.7yrs
    • Compensation: US$303.13k
  • Brian Dow (50yo)

    CFO, Senior VP of Finance & Administration

    • Tenure: 3.8yrs
    • Compensation: US$381.39k
  • Richard Nuccitelli

    Chief Science Officer

    • Tenure: 4.8yrs
  • Holly Hartman

    Vice President of Business Development & Corporate Strategy

    • Tenure: 3.1yrs

Board Members

  • Tom Fogarty (85yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$174.05k
  • Darrin Uecker (53yo)

    President

    • Tenure: 4yrs
    • Compensation: US$569.44k
  • Ken Clark (60yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$170.39k
  • Bob Duggan (75yo)

    Chairman of the Board

    • Tenure: 1.8yrs
    • Compensation: US$186.39k
  • Mitch Levinson (59yo)

    Director

    • Tenure: 0.5yrs
  • Maky Zanganeh (49yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$171.39k
  • Manmeet Soni (41yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$180.05k

Company Information

Pulse Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pulse Biosciences, Inc.
  • Ticker: PLSE
  • Exchange: NasdaqCM
  • Founded: 2014
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$343.302m
  • Shares outstanding: 20.77m
  • Website: https://www.pulsebiosciences.com

Number of Employees


Location

  • Pulse Biosciences, Inc.
  • 3957 Point Eden Way
  • Hayward
  • California
  • 94545
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PLSENasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDMay 2016
6L8DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2016

Biography

Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cell ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:44
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.